Oncology Abstracts

Contents

• 7th PacRim Meeting Poster Presentations
• • (1)
  • • S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer

      oa0001p001
    • BMP4 is a bonafide breast cancer metastasis suppressor

      oa0001p002
    • Using coordination chemistry and nanotechnology to develop a brand new class of therapeutics

      oa0001p003
    • A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer

      oa0001p004
    • Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome

      oa0001p005
    • ROCK educates cancer-associated fibroblasts via secreted Creld2 to create a tumour-promoting microenvironment

      oa0001p006
    • Estrogen receptor positive luminal progenitors the cancer cell origin for Estrogen receptor positive breast cancer

      oa0001p007
    • Mechanisms underlying uncontrolled genome doubling in breast cancer

      oa0001p008
    • Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer

      oa0001p009
    • Epi-transcriptomic alterations in ER-positive breast cancer

      oa0001p010
    • The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

      oa0001p011
    • Targeting AR in endocrine-resistant breast cancer

      oa0001p012
    • Single cell transcriptome analysis reveals human prostate cancer cells upregulate retinoic acid signalling in response to androgen withdrawal

      oa0001p013
    • Nuclear ErbB-2 activity modulates the interferon signaling pathway in breast cancer cells resistant to anti-ErbB-2 therapies

      oa0001p014
    • Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelia-mesenchymal transitions

      oa0001p015
    • AR chromatin binding is reprogrammed in the absence of FOXA1 in ER- breast cancers

      oa0001p016
    • Loss of FAM3B promotes prostate cancer progression by modulating glucose metabolism

      oa0001p017
    • Assessing alterations in organelle contacts during prostate cancer development

      oa0001p018
    • Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene

      oa0001p019
    • Circular RNAs add further diversity to AR isoform repertoire

      oa0001p020
    • Estrogen receptor alpha controls gene expression via translational offsetting

      oa0001p021
    • Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution

      oa0001p022
    • The Myoepithelium as a Risk Predictor in Ductal Carcinoma In Situ of the Breast

      oa0001p023
    • Lasofoxifene is an effective inhibitor of breast cancer lung and liver metastasis in a mammary intraductal (MIND) xenograft model of mutant ER[alpha]+ breast cancer

      oa0001p024
    • Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network

      oa0001p025
    • A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer progression

      oa0001p026
    • Estrogen maintains mammographic density via heparanase mediated induction of SDC-1 and -4

      oa0001p027
    • Immune signalling is a key driver of breast density and breast cancer risk

      oa0001p028
    • Translation of the ER[alpha]-PR crosstalk story to the clinic (the PIONEER study), and further preclinical exploration of the diverse role of progestins in ER-positive breast cancer

      oa0001p029
    • Androgen receptor binding sites are highly mutated in prostate cancer

      oa0001p030
    • New combination therapies for castration-resistant prostate cancer

      oa0001p031
    • Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer

      oa0001p032
    • LobSig, a prognostic signature for ILC

      oa0001p033
    • Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer

      oa0001p034
    • Therapeutic targeting of Ezh2 enhances PD-1 blockade by induction of interferon gamma response

      oa0001p035
    • Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target

      oa0001p036
    • Novel role of CBF[beta] as a regulator of breast cancer phenotype, progression and metastasis

      oa0001p037
    • Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer

      oa0001p038
    • Quest for the lost andromedin

      oa0001p039
    • Unravelling the role of cell plasticity in BrCa development and metastasis

      oa0001p040
    • Extending genetic portraits of human prostate cancer

      oa0001p041
    • PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

      oa0001p042
    • Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer

      oa0001p043
    • Epithelial mesenchymal transition, stromal density, and chemo-resistance in breast cancer (BrCa)

      oa0001p044
    • Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer

      oa0001p045
    • A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer

      oa0001p046
    • IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer

      oa0001p047
    • Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay

      oa0001p048
    • DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer

      oa0001p049
    • Preclinical development of CDDD3-14, a potent and selective inhibitor of CDK4/6 for the treatment of breast cancer

      oa0001p050
    • Targeting HP1-alpha for prevention and treatment of neuroendocrine prostate cancer

      oa0001p051
    • Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro

      oa0001p052